Triple-negative breast cancer is more aggressive than other forms. It’s more likely to have spread beyond your breast at the time it’s found, and there’s a higher chance it will come back within the first 3 years after treatment. It’s also more likely to be fatal within the first...
Triple negative breast cancer is more often responsive to chemotherapy than hormone receptor positive (ER+/PR+) breast cancer. On the other hand, long-term hormonal treatments (tamoxifen, aromatase inhibitors) used for ER+ subtypes are not effective for triple negative breast cancer since estrogen ...
This study of patients with early-stage triple-negative breast cancer not treated with adjuvant or neoadjuvant chemotherapy analyzes the association
Breast cancer is a heterogeneous disease, and within the HER-2 positive subtype this is highly exemplified by the presence of substantial phenotypical and clinical heterogeneity, mostly related to hormonal receptor (HR) expression. It is well known how HER-2 positivity is commonly associated with ...
After her diagnosis of hormone-negative breast cancer, health journalist Patricia Prijatel did what any reporter would do: start investigating the disease, how it occurs, how it's treated, and how to keep it from recurring. While she learned that important research on triple-negative breast ...
Breast cancer is the most frequently diagnosed cancer globally and the leading cause of cancer-related deaths among women. Approximately 15% of breast
三阴性乳腺癌triple negative breast cancer.pdf,Triple negative breast cancer- update on classification and • Basal like breast cancer and triple negative cancer biomarkers • Heterogeneity of triple negative cancer • Further classification of trip
Conclusion: Be alert for the presence of malignancy when a breast cancer patient presents with DM, a test for dermatologists, rheumatologists, and oncologists. This case demonstrated the effectiveness of breast-conserving surgery combined with radiotherapy for early-stage triple-negative...
The development of immunotherapy agents has revolutionized the field of oncology. The only FDA-approved immunotherapeutic approach in breast cancer consists of immune checkpoint inhibitors, yet several novel immune-modulatory strategies are being activel
Triple-negative breast cancer (TNBC), a highly aggressive subtype of breast cancer, negatively expresses estrogen receptor, progesterone receptor, and the human epidermal growth factor receptor 2 (HER2). Although chemotherapy is the main form of treatmen